Physician profile
Sameer Siddique
NPI 1053544130
$849.78
in general payments reported to CMS, 2019-2025
15 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2021: $139 · 2022: $65.72 · 2023: $146 · 2024: $217 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $228.47 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor |
| Abbvie INC. | $141.75 | 2022-2025 | Skyrizi |
| Medtronic, INC. | $140.74 | 2024-2025 | Nexpowder, Sharkcore |
| Celgene Corporation | $115.47 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $31.86 | 2025 | Rezdiffra |
| Emd Serono, INC. | $25.99 | 2024 | |
| Janssen Pharmaceuticals, INC | $25.00 | 2023 | Xarelto |
| Novo Nordisk INC | $24.00 | 2025 | Wegovy |
| Pfizer INC. | $19.82 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $19.06 | 2024 | Fasenra |
| Abbott Laboratories | $18.85 | 2022 | |
| Capsovision, INC. | $15.25 | 2024 | Capsocam Plus |
| Conmed Corporation | $14.90 | 2023 | Conmed Hemostasis |
| Takeda Pharmaceuticals U.S.A., INC. | $14.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Siddique listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.